This is a cache of https://www.uibk.ac.at/en/pharmazie/pharmakologie/calciumchannelprojects/nadine-ortner/. It is a snapshot of the page at 2025-04-24T00:44:17.471+0200.
Nadine Ortner – Universität Innsbruck

Mag. Nadine J. Ortner, PhD 

University Assistant (Post-Doc)

Email: Nadine.Ortner@uibk.ac.at 
Phone: +43-(0)512-507 - 58815
ORCID: https://orcid.org/0000-0003-3882-3283Graduate Program: https://cavx.at/group-ortner/

FG 3500 Multisystem study of phathogenic CACNA1D variants
RESEARCH INTEREST

I am particularly interested in deciphering the role of voltage-gated Ca2+ channels in brain disorders such as Parkinson’s disease, autism spectrum disorder or epilepsies and their pharmacological modulation as a potential therapeutic intervention. For my studies I employ molecular (cloning, generation of stable cell lines), electrophysiological (heterologous expression systems, brain slices), immunohistochemical and pharmacological methods.

SHORT CURRICULUM

Born: April 7, 1987
 
2001 – 2006      
Commercial academy with focus on information technology, Villach, Austria
 
2006 – 2012      
Diploma Program in Molecular Biology, University of Vienna, Austria
 
2012 – 2017      
PhD Program Pharmaceutical Sciences, Department of Pharmacology and Toxicology, University of Innsbruck, Austria (external member of the FWF-funded excellence PhD program “Molecular Cell Biology and Oncology (MCBO)”)
 
2017 – 2019      
Postdoctoral research fellow, Department of Pharmacology and Toxicology, University of Innsbruck, Austria
 
2019 – present
University assistant, Erika-Cremer habilitation fellowship of the University of Innsbruck, Austria

SCIENTIFIC AWARDS / FELLOWSHIPS / RESEARCH FUNDING

  • 2023    Austrian Science Fund (FWF) for the study of selective Cav1.3 inhibition for the treatment of human gain-of-function CACNA1D channelopathies (project within the CavX PhD excellence program )
  • 2021    Austrian Science Fund (FWF) for the study of the dopamine system in a neurodevelopmental disorder mouse model
  • 2019    Habilitation fellowship of the Erika-Cremer excellence program of the University of Insbruck
  • 2019    Poster & Travel Award (FASEB The Ion Channel Regulation Conference: Molecules to Disease, Lisbon)                           
  • 2018    Tyrolean Science Fund (TWF) for the study of subtype-selective Inhibitors of voltage-gated Ca2+ channels
  • 2017    Price by the Principality of Liechtenstein for scientific research at the University of Innsbruck
  • 2017    Jubiläumsfonds by the University of Innsbruck and the Medical University of Innsbruck for sponsorship of scientific cooperation projects
  • 2017    ALUMNI-I-MED Talk Prize (Life Science PhD Meeting Innsbruck, 2017)
  • 2015    PHOENIX Pharmazie Wissenschaftspreis for the publication “Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca2+ channel activators”, Nat Commun. 2014 Jun 19;5:3897
  • 2015    MCBO Best paper Award 2015

PUBLICATIONS

  • Filippini L, Ortner NJ, Kaserer T, Striessnig J.Cav1.3-selective inhibitors of voltage-gated L-type Ca2+ channels: fact or (still) fiction? Br J Pharmacol. 2023 Feb 14. doi: 10.1111/bph.16060. Online ahead of print.
  • Ortner NJ.CACNA1D-Related Channelopathies: From Hypertension to Autism. Handb Exp Pharmacol. 2023 Jan 3. doi: 10.1007/164_2022_626. Online ahead of print.
  • Török F, Tezcan K, Filippini L, Fernández-Quintero ML, Zanetti L, Liedl KR, Drexel RS, Striessnig J, Ortner NJ. Germline de novo variant F747S extends the phenotypic spectrum of CACNA1D Ca2+ channelopathies. Hum Mol Genet. 2023 Feb 19;32(5):847-859. doi: 10.1093/hmg/ddac248.
  • Siller A, Hofer NT, Tomagra G, Burkert N, Hess S, Benkert J, Gaifullina A, Spaich D, Duda J, Poetschke C, Vilusic K, Fritz EM, Schneider T, Kloppenburg P, Liss B, Carabelli V, Carbone E, Ortner NJ*, Striessnig J*. β2-subunit alternative splicing stabilizes Cav2.3 Ca2+ channel activity during continuous midbrain dopamine neuron-like activity. Elife. 2022 Jul 6;11:e67464. doi: 10.7554/eLife.67464.
  • El Ghaleb Y, Ortner NJ, Posch W, Fernández-Quintero ML, Tuinte WE, Monteleone S, Draheim HJ, Liedl KR, Wilflingseder D, Striessnig J, Tuluc P, Flucher BE, Campiglio M. Calcium current modulation by the γ1 subunit depends on alternative splicing of CaV1.1. J Gen Physiol. 2022 Sep 5;154(9):e202113028. doi: 10.1085/jgp.202113028. Epub 2022 Mar 29.
  • Nikonishyna YV, Ortner NJ, Kaserer T, Hoffmann J, Biskup S, Dafotakis M, Reetz K, Schulz JB, Striessnig J, Dohrn MF. Novel CACNA1A Variant p.Cys256Phe Disrupts Disulfide Bonds and Causes Spinocerebellar Ataxia. Mov Disord. 2022 Feb;37(2):401-404. doi: 10.1002/mds.28835. Epub 2021 Oct 14.
  • Ortner NJ.Voltage-Gated Ca2+ Channels in Dopaminergic Substantia Nigra Neurons: Therapeutic Targets for Neuroprotection in Parkinson's Disease? Front Synaptic Neurosci. 2021 Feb 26;13:636103. doi: 10.3389/fnsyn.2021.636103. eCollection 2021.
  • Ortner NJ, Kaserer T, Copeland JN, Striessnig J. De novo CACAN1D Ca2+ channelopathies: Clinical phenotypes and molecular mechanism, Pflugers Arch. 2020 Jun 24. doi: 10.1007/s00424-020-02418-w. Online ahead of print.
  • Striessnig J, Ortner NJ, Ca2+ channel blockers, In: Offermanns S., Rosenthal W. (eds) Encyclopedia of Molecular Pharmacology. Springer, Cham; https://doi.org/10.1007/978-3-030-21573-6_34-1
  • Hofer NT, Tuluc P, Ortner NJ, Nikonishyna YV, Fernándes-Quintero ML, Liedl KR, Flucher BE, Cox H, Striessnig J.Biophysical classification of a CACNA1D de novo mutation as a high-risk mutation for a severe neurodevelopmental disorder. Mol Autism. 2020 Jan 8;11:4. doi: 10.1186/s13229-019-0310-4. eCollection 2020.
  • Ortner NJ, Pinggera A, Hofer NT, Siller A, Brandt N, Raffeiner A, Vilusic K, Lang I, Blum K, Obermair GJ, Stefan E, Engel J, Striessnig J.RBP2 stabilizes slow Cav1.3 Ca2+ channel inactivation properties of cochlear inner hair cells. Pflugers Arch. 2020 Jan;472(1):3-25. doi: 10.1007/s00424-019-02338-4. Epub 2019 Dec 17.
  • Campiglio M, Costé de Bagneaux P, Ortner NJ, Tuluc P, Van Petegem F, Flucher BE.STAC proteins associate to the IQ domain of CaV1.2 and inhibit calcium-dependent inactivation. Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):1376-1381. doi: 10.1073/pnas.1715997115. Epub 2018 Jan 23.
  • Ortner NJ, Bock G, Dougalis A, Kharitonova M, Duda J, Hess S, Tuluc P, Pomberger T, Stefanova N, Pitterl F, Ciossek T, Oberacher H, Draheim H, Kloppenburg P, Liss B, Striessnig J.Lower affinity of isradipine for L-type Ca2+ channels during substantia nigra dopamine neuron-like activity: implications for neuroprotection in Parkinson's disease. J Neurosci. 2017 Jul 12;37(28):6761-6777. doi: 10.1523/JNEUROSCI.2946-16.2017. Epub 2017 Jun 7.
  • Kaur G, Pinggera A, Ortner NJ, Lieb A, Sinnegger-Brauns MJ, Yarov-Yarovoy V, Obermair GJ, Flucher BE, Striessnig J.A Polybasic Plasma Membrane Binding Motif in the I-II Linker Stabilizes Voltage-gated CaV1.2 Calcium Channel Function. J Biol Chem. 2015 Aug 21;290(34):21086-100. doi: 10.1074/jbc.M115.645671. Epub 2015 Jun 22.
  • Ortner NJ, Striessnig J.L-type calcium channels as drug targets in CNS disorders. Channels (Austin). 2016;10(1):7-13. doi: 10.1080/19336950.2015.1048936. Epub 2015 Jun 3. Review.
  • Striessnig J, Ortner NJ, Pinggera A.Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets? Curr Mol Pharmacol. 2015;8(2):110-22. Review.
  • Ortner NJ, Bock G, Vandael DH, Mauersberger R, Draheim HJ, Gust R, Carbone E, Tuluc P, Striessnig J Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca2+ channel activators. Nat Commun. 2014 Jun 19;5:3897. doi: 10.1038/ncomms4897.
  • Lieb A, Ortner NJ, Striessnig J, C-terminal modulatory domain controls coupling of voltage-sensing to pore opening in Cav1.3 L-type Ca2+ channels. Biophys J. 2014 Apr 1;106(7):1467-75. doi: 10.1016/j.bpj.2014.02.017.

 For publications in Pubmed click here

PRESS REPORTS

12/2024  FWF: Neue Forschungsgruppen starten (Forschungsgruppe „Multisystemische Studie von pathogenen CACNA1D-Varianten“)

09/2023  Von der Freude abzuschließen: Nadine ORTNER im Portrait

03/2023  Lebenswichtige Kalziumkanäle gemeinsam erforschen 

06/2023  Kontrollverlust mit Folgen 

03/2018  Liechtenstein-Preis zum 35. Mal verliehen 

02/2018  Gemeinsame Forschungsarbeit in den Neurowissenschaften wird gefördert 

11/2015  PHOENIX Preis 2015: Wissenschaftspreis für die AG Jörg STRIESSNIG

 

Nach oben scrollen